OpenAI unveiled its firstdomain‑specific frontier reasoning model, GPT‑Rosalind, on April 16 2026, marking a strategic pivot from general‑purpose AI toward vertical specialists in biology, drug discovery, and translational medicine.
Named after British chemist and DNA pioneer Rosalind Franklin, the model signals OpenAI’s commitment to building highly specialized tools that can navigate the complex, multi‑step workflows typical of modern scientific research.
GPT‑Rosalind is optimized for long‑horizon, tool‑heavy scientific workflows, supporting evidence synthesis, hypothesis generation, experimental planning, and multi‑step research tasks that previously required extensive manual effort.
On the BixBench bioinformatics benchmark, it achieved a Pass@1 score of 0.751, surpassing GPT‑5.4 (0.732), Grok 4.2 (0.698) and Gemini 3.1 Pro (0.550), demonstrating superior accuracy in retrieving correct answers on the first attempt.
In an unpublished evaluation with Dyno Therapeutics using proprietary RNA sequences, the model ranked above the 95th percentile of human experts for sequence‑to‑function prediction and at the 84th percentile for de‑novo sequence generation, underscoring its domain expertise.
On LABBench2, GPT‑Rosalind outperformed GPT‑5.4 on six of eleven task families, with the most pronounced improvement in CloningQA, which requires end‑to‑end design of DNA and enzyme reagents for molecular cloning protocols.
The new Life Sciences research plugin for Codex links the model to more than 50 public scientific resources, including AlphaFold, PubMed, UniProt, and ClinVar, enabling seamless data retrieval and integration within a single workflow.
Access is currently restricted to qualified U.S. enterprise customers through OpenAI’s Trusted Access Program, with initial partners such as Amgen, Moderna, Novo Nordisk, Thermo Fisher Scientific, the Allen Institute, Genentech, and the UCSF School of Pharmacy.
For researchers and scientists, the model is not intended to replace human labor but to automate hours‑long manual tasks like literature synthesis and protocol design, freeing graduate students and postdocs to focus on higher‑level analysis.
Developers can use the free Codex Life Sciences research plugin on GitHub to connect mainstream models like GPT‑5.4 to biological databases, expanding experimental capabilities even without direct Rosalind access.
Geographically, Europe and India are excluded from the initial rollout, creating a near‑term access asymmetry that may influence global research collaboration patterns and exacerbate existing inequities.
During the preview phase, usage of GPT‑Rosalind does not consume existing OpenAI credits or tokens for eligible organizations, subject to abuse‑prevention safeguards, and a subscription model introduced on April 9 2026 sets a $200 per month fee for qualified enterprise seats after the free period.
These performance and accessibility characteristics suggest that GPT‑Rosalind could dramatically shorten drug‑discovery cycles by automating target validation, primer design, and experimental planning, potentially lowering R&D costs and accelerating time‑to‑market for novel therapeutics.
While competitors such as DeepMind’s AlphaFold and specialized cheminformatics platforms continue to excel in structure prediction and molecular modeling, GPT‑Rosalind’s strength lies in its ability to orchestrate multi‑modal data, generate hypotheses, and interface with a broad ecosystem of databases, positioning it as a complementary rather than replacement technology.
Nevertheless, the limited Trusted Access program raises concerns about data privacy, intellectual property protection, and the need for rigorous validation before clinical deployment, prompting calls for transparent governance and possibly tiered licensing models.
Looking ahead, OpenAI plans to expand the plugin ecosystem, improve multilingual support, and eventually broaden access beyond the United States, which could democratize advanced scientific AI and reshape how biotech innovation is conducted worldwide.